Reduction in use of cyproterone/ethinylestradiol (Diane-35 and generics) after risk minimization measures in the Netherlands, UK and Italy

Fernie J.A. Penning-van Beest; Irene D. Bezemer; Elisabeth Smits; Luis A. García Rodríguez; Lucía Cea Soriano; Francesco Lapi; Monica Simonetti; Alex Asiimwe; Ron M.C. Herings

doi:https://doi.org/10.1016/j.contraception.2020.05.010

Reduction in use of cyproterone/ethinylestradiol (Diane-35 and generics) after risk minimization measures in the Netherlands, UK and Italy

Fernie J.A. Penning-van Beest, Irene D. Bezemer, Elisabeth Smits, Luis A. García Rodríguez, Lucía Cea Soriano, Francesco Lapi, Monica Simonetti, Alex Asiimwe, Ron M.C. Herings

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Objectives: To study the effect of risk minimization measures taken in 2013 for cyproterone acetate/ethinylestradiol (CPA/EE) on initiation, concomitant use of other hormonal contraceptives (HC) and potential indications. Study design: This retrospective study included data on CPA/EE use in 2011–2017 from the Netherlands, UK, and Italy. Results: The initiation rate of CPA/EE decreased by 44%–91% between 2011 and 2017. Proportions with concomitant use of other HC (<3%) and approved indications did not change over time. Conclusion: Apart from a strong reduction in CPA/EE use following risk minimization measures, no major changes were observed regarding concomitant use of other HC or potential reasons for use.

Original language	English
Pages (from-to)	243-245
Number of pages	3
Journal	Contraception
Volume	102
Issue number	4
DOIs	https://doi.org/10.1016/j.contraception.2020.05.010
Publication status	Published - Oct 2020

Keywords

Acne
Cyproterone acetate/ethinylestradiol
Diane-35
Prescribing
Real world data
Risk minimization

Access to Document

https://doi.org/10.1016/j.contraception.2020.05.010

Cite this

Penning-van Beest, F. J. A., Bezemer, I. D., Smits, E., García Rodríguez, L. A., Cea Soriano, L., Lapi, F., Simonetti, M., Asiimwe, A., & Herings, R. M. C. (2020). Reduction in use of cyproterone/ethinylestradiol (Diane-35 and generics) after risk minimization measures in the Netherlands, UK and Italy. Contraception, 102(4), 243-245. https://doi.org/10.1016/j.contraception.2020.05.010

@article{4aea81abda3442b39247193be9dd93e6,

title = "Reduction in use of cyproterone/ethinylestradiol (Diane-35 and generics) after risk minimization measures in the Netherlands, UK and Italy",

abstract = "Objectives: To study the effect of risk minimization measures taken in 2013 for cyproterone acetate/ethinylestradiol (CPA/EE) on initiation, concomitant use of other hormonal contraceptives (HC) and potential indications. Study design: This retrospective study included data on CPA/EE use in 2011–2017 from the Netherlands, UK, and Italy. Results: The initiation rate of CPA/EE decreased by 44%–91% between 2011 and 2017. Proportions with concomitant use of other HC (<3%) and approved indications did not change over time. Conclusion: Apart from a strong reduction in CPA/EE use following risk minimization measures, no major changes were observed regarding concomitant use of other HC or potential reasons for use.",

keywords = "Acne, Cyproterone acetate/ethinylestradiol, Diane-35, Prescribing, Real world data, Risk minimization",

author = "{Penning-van Beest}, {Fernie J.A.} and Bezemer, {Irene D.} and Elisabeth Smits and {Garc{\'i}a Rodr{\'i}guez}, {Luis A.} and {Cea Soriano}, Luc{\'i}a and Francesco Lapi and Monica Simonetti and Alex Asiimwe and Herings, {Ron M.C.}",

year = "2020",

month = oct,

doi = "https://doi.org/10.1016/j.contraception.2020.05.010",

language = "English",

volume = "102",

pages = "243--245",

journal = "Contraception",

issn = "0010-7824",

publisher = "Elsevier USA",

number = "4",

}

Penning-van Beest, FJA, Bezemer, ID, Smits, E, García Rodríguez, LA, Cea Soriano, L, Lapi, F, Simonetti, M, Asiimwe, A & Herings, RMC 2020, 'Reduction in use of cyproterone/ethinylestradiol (Diane-35 and generics) after risk minimization measures in the Netherlands, UK and Italy', Contraception, vol. 102, no. 4, pp. 243-245. https://doi.org/10.1016/j.contraception.2020.05.010

TY - JOUR

T1 - Reduction in use of cyproterone/ethinylestradiol (Diane-35 and generics) after risk minimization measures in the Netherlands, UK and Italy

AU - Penning-van Beest, Fernie J.A.

AU - Bezemer, Irene D.

AU - Smits, Elisabeth

AU - García Rodríguez, Luis A.

AU - Cea Soriano, Lucía

AU - Lapi, Francesco

AU - Simonetti, Monica

AU - Asiimwe, Alex

AU - Herings, Ron M.C.

PY - 2020/10

Y1 - 2020/10

N2 - Objectives: To study the effect of risk minimization measures taken in 2013 for cyproterone acetate/ethinylestradiol (CPA/EE) on initiation, concomitant use of other hormonal contraceptives (HC) and potential indications. Study design: This retrospective study included data on CPA/EE use in 2011–2017 from the Netherlands, UK, and Italy. Results: The initiation rate of CPA/EE decreased by 44%–91% between 2011 and 2017. Proportions with concomitant use of other HC (<3%) and approved indications did not change over time. Conclusion: Apart from a strong reduction in CPA/EE use following risk minimization measures, no major changes were observed regarding concomitant use of other HC or potential reasons for use.

AB - Objectives: To study the effect of risk minimization measures taken in 2013 for cyproterone acetate/ethinylestradiol (CPA/EE) on initiation, concomitant use of other hormonal contraceptives (HC) and potential indications. Study design: This retrospective study included data on CPA/EE use in 2011–2017 from the Netherlands, UK, and Italy. Results: The initiation rate of CPA/EE decreased by 44%–91% between 2011 and 2017. Proportions with concomitant use of other HC (<3%) and approved indications did not change over time. Conclusion: Apart from a strong reduction in CPA/EE use following risk minimization measures, no major changes were observed regarding concomitant use of other HC or potential reasons for use.

KW - Acne

KW - Cyproterone acetate/ethinylestradiol

KW - Diane-35

KW - Prescribing

KW - Real world data

KW - Risk minimization

UR - http://www.scopus.com/inward/record.url?scp=85086507177&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.contraception.2020.05.010

DO - https://doi.org/10.1016/j.contraception.2020.05.010

M3 - Article

C2 - 32470466

SN - 0010-7824

VL - 102

SP - 243

EP - 245

JO - Contraception

JF - Contraception

IS - 4

ER -

Reduction in use of cyproterone/ethinylestradiol (Diane-35 and generics) after risk minimization measures in the Netherlands, UK and Italy

Abstract

Keywords

Access to Document

Other files and links

Cite this